drug
ganciclovir
Marketedupdated 3mo agoby $BLCO Bausch & Lomb Corp
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 2Small molecule drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 8 investigational indications.
all catalysts(5)
approval · 5
Sep 15, 2009
approval
$BLCO17.20-1.43%
ZIRGAN (GANCICLOVIR) — FDA approval
ganciclovir
→
Feb 26, 2014
approval
$BLCO17.20-1.43%
ZIRGAN (GANCICLOVIR) — FDA approval
ganciclovir
→
Apr 29, 2014
approval
$BLCO17.20-1.43%
ZIRGAN (GANCICLOVIR) — FDA approval
ganciclovir
→
May 12, 2014
approval
$BLCO17.20-1.43%
ZIRGAN (GANCICLOVIR) — FDA approval
ganciclovir
→
Jan 20, 2026
approval
$BLCO17.20-1.43%
ZIRGAN (GANCICLOVIR) — FDA approval
ganciclovir
→
Trials studying ganciclovir
- phase2Study Evaluating the Efficacy and Safety of Artesunate
- —Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
- phase2Letermovir for CMV Prevention After Lung Transplantation
- phase1Phase 1 Study of GEN2 in Patients With Advanced Solid Tumors
- phase4Maribavir vs. Valganciclovir for CMV Prophylaxis in High-Risk Kidney Transplant Recipients
- phase2An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas
- phase2Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid Malignancies
- phase1Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPC
Patent cliff
source: FDA Orange Bookfirst barrier falls
Sep 2, 2034
~8.0 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (1)
- Sep 2, 2034formulationUS 9486530
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 38m ago
Found something off?
comments(0)
5-min edit window · permanent after that